The consequence of LDN’s antagonism towards the μ-opioid receptor is the direct inhibition of endorphin synthesis and the inhibition of EGFr, which leads to the blocking of the epithelial-mesenchymal transition of cancer cells. The gene discussed is EGFR; the disease is cancer.